Nexobrid (Concentrate Of Proteolytic Enzymes Enriched In Bromelain)

Concentrate of proteolytic enzymes enriched in bromelain, the active ingredient in Nexobrid, is a proteolytic enzyme presented as a topical concentrate for cutaneous use. It facilitates enzymatic debridement of deep and superficial partial‑thickness burn wounds in patients requiring rapid removal of necrotic tissue.

GNH USA supplies Nexobrid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, burn centres and clinics worldwide, and complies with EU regulatory standards for medical devices and pharmaceuticals.

Nexobrid is used for enzymatic debridement of burn injuries, facilitating removal of necrotic tissue in partial‑thickness burns. - Deep partial‑thickness burns: achieves rapid debridement of necrotic tissue while preserving viable dermis. - Superficial partial‑thickness burns: provides selective removal of dead tissue with minimal impact on healthy skin. - Burn wound management: supports early assessment of wound depth and promotes faster healing by clearing necrotic debris.

Nexobrid may cause local and systemic reactions following topical application.

Common Side Effects: - Pain at the application site: mild to moderate discomfort during exposure. - Erythema: redness of surrounding skin. - Edema: localized swelling. - Increased wound exudate: temporary rise in fluid discharge. - Itching: mild pruritus around treated area. - Transient hyperemia: temporary increase in blood flow.

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis: requires immediate medical attention. - Deep tissue necrosis beyond target area: may impair healing. - Systemic hypotension: due to absorption of proteolytic enzymes. - Secondary infection: risk if wound care is inadequate. - Scarring or delayed wound closure: in cases of excessive debridement. - Systemic hypersensitivity: rash, fever, or respiratory symptoms.

When using Nexobrid, follow clinical guidelines and monitor patients closely. - Application by trained personnel: ensure proper wound assessment before use. - Avoid use on infected wounds: risk of systemic spread. - Do not exceed recommended exposure time: follow clinician instructions. - Monitor for allergic reactions: discontinue if signs appear. - Store at ambient temperature (below 25°C): keep in original container, protect from moisture and light.

Nexobrid may interact with other agents affecting proteolysis or wound healing.

Major Interactions (Avoid): - Systemic protease inhibitors (e.g., aprotinin): may reduce enzymatic activity. - Concurrent use of other topical debriding agents: risk of excessive tissue damage.

Moderate Interactions (Monitor Closely): - Topical antibiotics: monitor for local irritation. - Anticoagulants: observe for increased bleeding at the wound site. - Immunosuppressants: watch for heightened infection risk.